LEXEO THERAPEUTICS INC (LXEO)

US52886X1072 - Common Stock

7.64  -0.05 (-0.65%)

After market: 7.633 -0.01 (-0.09%)

News Image
18 hours ago - Chartmill

Which stocks are gapping on Wednesday?

Gap analysis on 2024-11-13: gap up and gap down stocks in today's session.

News Image
21 hours ago - Lexeo Therapeutics

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results...

News Image
15 days ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's...

News Image
23 days ago - Lexeo Therapeutics

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference...

News Image
a month ago - Market News Video

Lexeo Therapeutics Becomes Oversold (LXEO)

News Image
2 months ago - Market News Video

Relative Strength Alert For Lexeo Therapeutics

News Image
2 months ago - Lexeo Therapeutics

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - September 2024...

News Image
3 months ago - InvestorPlace

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024

LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

News Image
3 months ago - BusinessInsider

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexeo Therapeutics (NASDAQ:LXEO) just reported results for the second quarter o...

News Image
3 months ago - Lexeo Therapeutics

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no...

News Image
4 months ago - Investor's Business Daily

Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout

The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease.

News Image
4 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline ...

News Image
4 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering...

News Image
4 months ago - Lexeo Therapeutics

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors ...

News Image
6 months ago - Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights...

News Image
6 months ago - Lexeo Therapeutics

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences...

News Image
7 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated...

News Image
8 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds and Woodline Partners LP

News Image
8 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing ...

News Image
8 months ago - Lexeo Therapeutics

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into...

News Image
8 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S.

News Image
8 months ago - Lexeo Therapeutics

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing...

News Image
9 months ago - Lexeo Therapeutics

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments...